Stay updated on Upadacitinib vs Methotrexate in RA Clinical Trial
Sign up to get notified when there's something new on the Upadacitinib vs Methotrexate in RA Clinical Trial page.

Latest updates to the Upadacitinib vs Methotrexate in RA Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision tag updated from v3.6.2 to v3.6.3 to reflect a minor update to the page's documentation/version history.SummaryDifference0.0%

- Check20 days agoChange DetectedFooter information updated to reflect a site revision (v3.6.2) and to add standard government links and release notes. The update affects site-wide navigation and informational footers, not the study content or details on the Study Details page.SummaryDifference100%

- Check27 days agoChange DetectedA Rheumatoid arthritis topic label was added, along with a related topics section and a MedlinePlus Genetics link. This helps place the study in the broader RA context and guides users to additional authoritative resources.SummaryDifference0.1%

- Check34 days agoChange DetectedRecruitment status updated to indicate no participants are being sought and new user-guidance sections were added to help readers understand and join the study; some related topics were removed or reformatted.SummaryDifference0.2%

- Check42 days agoChange DetectedRheumatoid arthritis was added to the related topics, and a link to MedlinePlus Genetics was included under related topics. The page revision label was updated from v3.5.4 to v3.5.5.SummaryDifference0.1%

- Check56 days agoChange DetectedRelated topics in the MedlinePlus section were removed, including the rheumatoid arthritis link, the related topics header, and the MedlinePlus Genetics link. This reduces the set of quick-access topic references shown on the page.SummaryDifference0.1%

Stay in the know with updates to Upadacitinib vs Methotrexate in RA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Upadacitinib vs Methotrexate in RA Clinical Trial page.